How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?

inflammatory bowel disease medication optimization monitoring pharmacist safety

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 16 05 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

The World Health Organization has recommended that the management of chronic diseases such as inflammatory bowel disease (IBD) should be undertaken using an integrated approach delivered by a multidisciplinary team. Although the composition of an IBD multidisciplinary team has been well described, the inclusion of an IBD pharmacist as a core member has been more recent, with variable uptake within IBD services internationally. While pharmacists continue to play the traditional role of safe prescribing and monitoring of immunosuppressive therapies, their role within the IBD team is rapidly expanding; however, the value, in terms of both clinical outcomes as well as financial savings (where available), which they add to IBD services has been less well described. In this narrative review, we perform a comprehensive evaluation of the literature detailing the expanding roles that IBD pharmacists play and describe opportunities that exist for integrated pharmacists to add value to IBD service delivery. Medication and adherence counseling, immunosuppressive monitoring, uptake of biosimilars, therapeutic drug monitoring, health promotion and prevention appear to be key areas where integrated pharmacists can add the most value to IBD patients and services. In particular, integrated IBD pharmacists can improve patient outcomes via rigorous monitoring pre and post initiation of drug therapies; focused medication counseling; advice on improving adherence; implementation of novel approaches to medication usage, and; strategies to help sustain IBD service delivery. These data can be used to further build a case for those seeking to add pharmacists to their team/services. Future studies should focus on evaluating the impact of an integrated IBD pharmacist on quality-of-care delivery together with the clinical and financial value added to IBD services compared to services that lack an integrated IBD pharmacist role. Integration of inflammatory bowel disease (IBD) pharmacists adds value to IBD services by improving immunosuppressive monitoring, increasing patients’ understanding and adherence to drug regimens and contributing to sustainable delivery of quality care, via novel models of care and innovative approaches to drug therapy.

Autres résumés

Type: plain-language-summary (eng)
Integration of inflammatory bowel disease (IBD) pharmacists adds value to IBD services by improving immunosuppressive monitoring, increasing patients’ understanding and adherence to drug regimens and contributing to sustainable delivery of quality care, via novel models of care and innovative approaches to drug therapy.

Identifiants

pubmed: 39207321
pii: 7745062
doi: 10.1093/ibd/izae196
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NHMRC Emerging Leader 2 Fellowship

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Patrick Hilley (P)

Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.
Department of Pharmacy, The Austin Hospital, Melbourne, Australia.

Darren Wong (D)

Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.

Peter De Cruz (P)

Department of Gastroenterology, The Austin Hospital, Melbourne, Australia.
Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.

Classifications MeSH